(203 days)
Not Found
Yes
The device name explicitly includes "AI-Rad Companion," and the description mentions "AI-Rad Companion Engine platform."
No.
The document describes a post-processing image analysis software for evaluating MR brain images, which assists in diagnosis and monitoring, not in providing direct treatment or therapy.
Yes
The device assists clinicians in analyzing and evaluating MR brain images by segmenting and quantifying brain structures, comparing them to normative data, and presenting results, which are all integral parts of a diagnostic process to identify abnormalities or disease states.
Yes
The device is described as "post-processing image analysis software" and an "enhancement to the predicate, syngo.MR Application". The description focuses on software functionalities like segmentation, quantitative analysis, and comparison with normative data. While it processes MR images, the device itself is presented as a software tool for analyzing existing image data, not a hardware component for image acquisition or a physical device. The modifications listed are also software-related (intended use statement, deviation map, architectural enhancement for cloud deployment).
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended for use in vitro for the examination of specimens, including blood, tissue, and urine, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the safety and compatibility with potential recipients, or to monitor therapeutic measures.
- Device Function: AI-Rad Companion Brain MR is a software that analyzes MR brain images. These are images acquired from the human body, not specimens taken from the body for in vitro examination.
- Intended Use: The intended use is to assist clinicians in viewing, analyzing, and evaluating MR brain images. This is image analysis, not the examination of biological specimens.
Therefore, AI-Rad Companion Brain MR falls under the category of medical image analysis software, not an In Vitro Diagnostic device.
No
The provided text does not contain any explicit statements indicating that the FDA has reviewed, approved, or cleared a Predetermined Change Control Plan (PCCP) for this specific device.
Intended Use / Indications for Use
AI-Rad Companion Brain MR is a post-processing image analysis software that assists clinicians in viewing, analyzing and evaluating MR brain images.
AI-Rad Companion Brain MR provides the following functionalities:
- Automatic segmentation and quantitative analysis of individual brain structures
- Quantitative comparison of each brain structure with normative data from a healthy population
- Presentation of results for reporting that includes all numerical values as well as visualization of these results.
Product codes
LLZ, LNH
Device Description
AI-Rad Companion Brain MR is an enhancement to the predicate, syngo.MR Application (K182904). Just as in the predicate, AI-Rad Companion Brain MR addresses the automatic quantification and visual assessment of the volumetric properties of various brain structures based on T1 MPRAGE datasets. These datasets are acquired as part of a typical head MR acquisition. The results are directly archived in PACS as this is the standard location for reading by radiologist. From a predefined list of 30 structures (e.g. Hippocampus, Caudate, Left Frontal Grey Matter, etc.), volumetric properties are calculated as absolute and normalized volumes with respect to the total intercranial volume. The normalized values for a given patient are compared against age-matched mean and standard deviations obtained from a population of healthy reference subjects.
As an update to the previously cleared device, the following modifications have been made:
-
- Modified Intended Use Statement
-
- Addition of a customizable deviation map
-
- Architectural enhancement for the clinical extension to be deployed with the AI-Rad Companion Engine platform in a cloud-based environment
Mentions image processing
Yes
Mentions AI, DNN, or ML
AI-Rad Companion Brain MR
Input Imaging Modality
MR brain images, T1 MPRAGE datasets
Anatomical Site
Brain
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Clinicians, radiologist, healthcare professionals familiar with the post processing of magnetic resonance images.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Non-clinical tests were conducted to test the functionality of AI-Rad Companion Brain MR. Software validation and bench testing have been conducted to assess the performance claims as well as the claim of substantial equivalence to the predicate device.
Software "bench" testing in the form of Unit. System and Integration tests were performed to evaluate the performance and functionality of the new features and software updates. All testable requirements in the Requirement Specifications and the Risk Analysis have been successfully verified and traced in accordance with the Siemens Healthineers DH product development (lifecvcle) process. Human factor usability validation is addressed in system testing and usability validation test records. Software verification and regression testing have been performed successfully to meet their previously determined acceptance criteria as stated in the test plans.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
No clinical tests were conducted to test the performance and functionality of the modifications introduced within AI-Rad Companion Brain MR. Verification and validation of the enhancements and improvements have been performed and these modifications have been validated for their intended use. The data from these activities were used to support the subject device and the substantial equivalence argument.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
June 17, 2020
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Siemens Medical Solutions USA, Inc. % Ms. Lauren Bentley Senior Manager, Regulatory Affairs 40 Liberty Blvd., Mail Code 65-3 MALVERN PA 19355
Re: K193290
Trade/Device Name: AI-Rad Companion Brain MR Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: Class II Product Code: LLZ Dated: May 15, 2020 Received: May 19, 2020
Dear Ms. Bentley:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmp/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
1
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name AI-Rad Companion Brain MR
Indications for Use (Describe)
AI-Rad Companion Brain MR is a post-processing image analysis software that assists clinicians in viewing, analyzing and evaluating MR brain images.
AI-Rad Companion Brain MR provides the following functionalities:
- Automatic segmentation and quantitative analysis of individual brain structures
- Quantitative comparison of each brain structure with normative data from a healthy population
- Presentation of results for reporting that includes all numerical values as well as visualization of these results
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the Siemens Healthineers logo. The word "SIEMENS" is in teal, and the word "Healthineers" is in orange. To the right of the words are a series of orange dots arranged in a pattern.
510(k) SUMMARY FOR AI-RAD COMPANION BRAIN MR
Submitted by: Siemens Medical Solutions USA, Inc. 40 Liberty Boulevard Malvern, PA 19355 Date Prepared: November 25, 2019
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Devices Act of 1990 and 21 CFR §807.92.
1. Submitter
| Importer/Distributor | Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard
Malvern, PA 19355
Mail Code: 65-1A
Registration Number: 2240869 |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturing Site | Siemens Healthcare GmbH
Henkestrasse 127
Erlangen, Germany 91052
Registration Number: 3002808157 |
2. Contact Person
Lauren Bentley Senior Manager, Regulatory Affairs Siemens Medical Solutions USA, Inc. 40 Liberty Boulevard Mail Code: 65-3 Malvern, PA 19335 Phone: +1 (610) 241 - 6736 Email: lauren.bentley@siemens-healthineers.com
3. Device Name and Classification
| Product Name: | AI-Rad Companion Brain MR |
|---|---|
| Trade Name: | AI-Rad Companion Brain MR |
| Classification Name: | Picture Archiving and Communication System |
4
Image /page/4/Picture/0 description: The image shows the logo for Siemens Healthineers. The word "SIEMENS" is in teal, and the word "Healthineers" is in orange. To the right of the word "Healthineers" is a graphic of orange dots arranged in a circular pattern.
| Classification Panel: | Radiology |
|---|---|
| CFR Section: | 21 CFR §892.2050 |
| Secondary CFR Section: | 21 CFR §892.1000 |
| Device Class: | Class II |
| Product Code: | LLZ |
| Secondary Product Code: | LNH |
4. Predicate Device
| Product Name: | syngo.MR Applications |
|---|---|
| Propriety Trade Name: | syngo.MR Applications |
| 510(k) Number: | K182904 |
| Clearance Date: | July 5, 2019 |
| Classification Name: | Magnetic Resonance Diagnostic Device |
| Classification Panel: | Radiology |
| CFR Section: | 21 CFR §892.2050 |
| Secondary CFR Section: | 21 CFR §892.1000 |
| Device Class: | Class II |
| Primary Product Code: | LLZ |
| Secondary Product Code: | LNH |
| Recall Information: | N/A |
5. Intended Use
AI-Rad Companion Brain MR is a post-processing image analysis software that assists clinicians in viewing, analyzing and evaluating MR brain images.
AI-Rad Companion Brain MR provides the following functionalities:
- Automatic segmentation and quantitative analysis of individual brain structures ●
- Quantitative comparison of each brain structure with normative data from a healthy ● population
- Presentation of results for reporting that includes all numerical values as well as visualization of these results.
6. Device Description
AI-Rad Companion Brain MR is an enhancement to the predicate, syngo.MR Application (K182904). Just as in the predicate, AI-Rad Companion Brain MR addresses the automatic quantification and visual assessment of the volumetric properties of various brain structures based on T1 MPRAGE datasets. These datasets are acquired as part of a typical head MR acquisition. The results are directly archived in PACS as this is the standard location for reading by radiologist. From a predefined list of 30 structures (e.g. Hippocampus, Caudate, Left Frontal Grey Matter, etc.), volumetric properties are calculated as absolute and normalized volumes with respect to the total intercranial volume. The normalized values for a given patient are compared
5
Image /page/5/Picture/0 description: The image shows the Siemens Healthineers logo. The word "SIEMENS" is in teal, and the word "Healthineers" is in orange. To the right of the words is an orange graphic of several dots arranged in a circular pattern.
against age-matched mean and standard deviations obtained from a population of healthy reference subjects.
As an update to the previously cleared device, the following modifications have been made:
-
- Modified Intended Use Statement
-
- Addition of a customizable deviation map
-
- Architectural enhancement for the clinical extension to be deployed with the AI-Rad Companion Engine platform in a cloud-based environment
7. Technological Characteristics
The subject device, AI-Rad Companion Brain MR is substantially equivalent with regards to software, programming language, operating system, performance and technology (including algorithms). AI-Rad Companion Brain MR offers enhancements and improvements to the existing predicate device, syngo.MR Applications: Brain Morphometry (K182904). While these enhancements offer additional visualization capabilities, compared to the predicate device, the conclusions from all verification and validation data suggest that these modifications do not adversely affect the safety and effectiveness of the predicate device.
8. Nonclinical Tests
Non-clinical tests were conducted to test the functionality of AI-Rad Companion Brain MR. Software validation and bench testing have been conducted to assess the performance claims as well as the claim of substantial equivalence to the predicate device.
AI-Rad Companion has been tested to meet the requirements of conformity to multiple industry standards. Non-clinical performance testing demonstrates that AI-Rad Companion Brain MR complies with the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" (May 11, 2005) as well as with the following voluntary FDA recognized Consensus Standards listed in Table 1 below.
| Recognition
Number | Product Area | Title of Standard | Reference
Number and
Date | Standards
Development
Organization |
|-----------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------------|
| 5-114 | General | Medical Devices -
Application of usability
engineering to medical
devices [including
Corrigendum 1 (2016)] | 62366-1:
2015-02 | IEC |
| 5-40 | General | Medical Devices -
application of risk
management to medical
devices | 14971:2007 | ISO |
| 13-79 | Software/
Informatics | Medical device software -
software life cycle | 62304:
2006/A1:2016 | AAMI
ANSI
IEC |
6
Image /page/6/Picture/0 description: The image shows the Siemens Healthineers logo. The word "SIEMENS" is in teal, and the word "Healthineers" is in orange. To the right of the words is a graphic of orange dots arranged in a circular pattern.
| Recognition
Number | Product Area | Title of Standard | Reference
Number and
Date | Standards
Development
Organization |
|-----------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------------|
| | | processes [Including
Amendment 1 (2016)] | | |
| 12-300 | Radiology | Digital Imaging and
Communications in
Medicine (DICOM) Set | PS 3.1 – 3.20
(2016) | NEMA |
| 12-261 | Radiology | Information Technology –
Digital Compression and
coding of continuous -tone
still images: Requirements
and Guidelines [including:
Technical Corrigendum
1(2005)] | 10918-1
1994-02-15 | ISO
IEC |
Table 1: Voluntary Conformance Standards
Verification and Validation
Software documentation for a Moderate Level of Concern software, per FDA's Guidance Document "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" issued on May 11, 2005, is also included as part of this submission. The performance data demonstrates continued conformance with special controls for medical devices containing software. Non-clinical tests were conducted on the subject device during product development.
Software "bench" testing in the form of Unit. System and Integration tests were performed to evaluate the performance and functionality of the new features and software updates. All testable requirements in the Requirement Specifications and the Risk Analysis have been successfully verified and traced in accordance with the Siemens Healthineers DH product development (lifecvcle) process. Human factor usability validation is addressed in system testing and usability validation test records. Software verification and regression testing have been performed successfully to meet their previously determined acceptance criteria as stated in the test plans.
Siemens Healthineers adheres to the cybersecurity requirements as defined the FDA Guidance "Content of Premarket Submissions for Management for Cybersecurity in Medical Devices," issued October 2, 2014 by implementing a process of preventing unauthorized access, modifications, misuse or denial of use, or the unauthorized use of information that is stored, accessed, or transferred from a medical device to an external recipient.
9. Clinical Tests
No clinical tests were conducted to test the performance and functionality of the modifications introduced within AI-Rad Companion Brain MR. Verification and validation of the enhancements and improvements have been performed and these modifications have been validated for their intended use. The data from these activities were used to support the subject device and the substantial equivalence argument.
7
Image /page/7/Picture/0 description: The image contains the logo for Siemens Healthineers. The word "SIEMENS" is in teal, and the word "Healthineers" is in orange. To the right of the word "Healthineers" is a graphic of orange dots.
No animal testing has been performed on the subject device.
10. Safety and Effectiveness
The device labeling contains instructions for use and any necessary cautions and warnings to ensure safe and effective use of the device.
Risk management is ensured via ISO 14971:2007 compliance to identify and provide mitigation of potential hazards in a risk analysis early in the design phase and continuously throughout the development of the product. These risks are controlled via measures realized during software development, testing and product labeling.
Furthermore, the device is intended for healthcare professionals familiar with the post processing of magnetic resonance images.
11. Substantial Equivalence and Conclusion
AI-Rad Companion Brain MR is substantially equivalent to the follow predicate device (Table 2):
| Predicate Device | FDA Clearance
Number | FDA Clearance
Date | Main Product Code |
|-----------------------|-------------------------|-----------------------|-------------------|
| syngo.MR Applications | K182904 | July 5, 2019 | LLZ |
Table 2: Predicate device for AI-Rad Companion Brain MR
AI-Rad Companion Brain MR has the same intended use and technical characteristics compared to the predicate device, syngo.MR Applications (K182904), with respect to the software features, functionalities and core algorithms. The enhancements and improvements provided in AI-Rad Companion Brain MR increase the usability and reduce the complexity of the imaging workflow for the clinical user. The conclusions from all verification data suggest that these enhancements are equivalent with respect to safety and effectiveness of the predicate device. These modifications do not change the intended use of the product. Siemens is of the opinion that AI-Rad Companion Brain MR is substantially equivalent to the currently marketed device, syngo.MR. Applications (K182904).